Novel technologies in the treatment and monitoring of advanced and relapsed epithelial ovarian cancer. (23rd February 2017)

• Record Type: Journal Article
• Authors: Cunnea, Paula; Gowers, Sally; Moore, James E; Drakakis, Emmanuel; Boutelle, Martyn; Fotopoulou, Christina
• Is Part Of: Convergent science physical oncology. Volume 3:Number 1(2017)
• Publication Date: 2017-02-23
• Subjects: bioengineering -- treatment -- epithelial ovarian cancer; Medical physics -- Periodicals; Oncology -- Periodicals; Cancer -- Treatment -- Periodicals; 616.9940153
• DOI: 10.1088/2057-1739/aa5cf1
• Languages: English
• ISSNs: 2057-1739

Abstract

Abstract: Epithelial ovarian cancer (EOC) is the fifth most common cause of cancer death in females in the UK. It has long been recognized to be a set of heterogeneous diseases, with high grade serous being the most common subtype. The majority of patients with EOC present at an advanced stage (FIGO III–IV), and have the largest risk for disease recurrence from which a high percentage will develop resistance to chemotherapy. Despite continual advances in diagnostics, imaging, surgery and treatment of EOC, there has been little variation in the survival rates for patients with EOC. In this review we will introduce novel bioengineering advances in modelling the lymphatic system and real-time tissue monitoring to improve the clinical and therapeutic outcome for patients with EOC. We discuss the advent of the non-invasive 'liquid biopsy' in the surveillance of patients undergoing treatment and follow-up. Finally, we present new bioengineering advances for palliative care of patients to lessen symptoms of patients with ascites and improve quality of life.